ライフサイエンスコーパス: phospholamban

1 SR Ca2+-ATPase, and depressed phosphorylated phospholamban).

2 th coexpression of phosphomimetic mutants of phospholamban.

3 ructural determinants of SERCA regulation by phospholamban.

4 a, protein kinase Cepsilon, calcineurin, and phospholamban.

5 drenergic stimulation and phosphorylation of phospholamban.

6 diesterase 4 resulting in hypophosphorylated phospholamban.

7 ion of L-type calcium channel (Ca(v)1.2) and phospholamban.

8 er with reduced serine-16 phosphorylation of phospholamban.

9 reduced NO production, and dephosphorylated phospholamban.

10 t phosphorylation of ryanodine receptors and phospholamban.

11 eta(2)ARs under agonist stimulation, but not phospholamban.

12 the pentamer as the most stable oligomer for phospholamban.

13 nt with a decrease in the phosphorylation of phospholamban.

14 ned by a higher degree of phosphorylation of phospholamban.

15 -Ab) that binds to the cytoplasmic domain of phospholamban.

16 epressed levels of SERCA2 and phosphorylated phospholamban.

17 g proteins, including ryanodine receptor and phospholamban.

18 ch by characterising the pentameric state of phospholamban, a key player in the regulation of calcium

19 Activated Akt phosphorylates phospholamban, a process that does not require beta-adre

20 G myocytes had changes in LTCC, SERCA2a, and phospholamban abundance, which appear to be adaptations

21 tein phosphatase-1 activity, thus modulating phospholamban activity and secondarily, the sarcoplasmic

22 NKA function in a manner similar to the way phospholamban affects the related SR Ca-ATPase (inhibiti

23 We observed that phospholamban altered ATP-dependent calcium translocatio

24 Similarly, selective mutation of phospholamban amino acids critical for enhancing SR Ca(2

25 1 (I-1), a direct calcineurin substrate, and phospholamban, an indirect target, oscillated directly o

26 hain were reduced in hypothyroidism, whereas phospholamban and beta-myosin heavy chain were increased

27 protein S-nitrosylation, in general, and for phospholamban and cardiac troponin C S-nitrosylation, in

28 cardiac Ca(2+)-handling proteins, including phospholamban and cardiac troponin C, thereby playing an

29 isoproterenol-induced PKA phosphorylation of phospholamban and contractile responses in myocytes.

30 pha (PKCalpha) can both lower phosphorylated phospholamban and depress myocyte calcium cycling.

31 ion was maintained, whereas, oscillations in phospholamban and I-1 phosphorylation were lost.

32 arcoplasmic reticulum for phosphorylation of phospholamban and increases in myocyte contraction.

33 inhibitor-1, promoting dephosphorylation of phospholamban and inhibition of the sarcoplasmic reticul

34 n blot analysis showed an induction of total phospholamban and its phosphorylated form in inguinal fa

35 ding insights into the physiological role of phospholamban and its regulatory effect on SERCA transpo

36 balance and spontaneous SR Ca2+ cycling, ie, phospholamban and L-type Ca2+ channels (and likely other

37 tiple modes of interaction between SERCA and phospholamban and observed that once a particular mode o

38 tudies revealed increased phosphorylation of phospholamban and p70S6K.

39 nificantly attenuates PKA phosphorylation of phospholamban and rapidly reduces contraction rate incre

40 ectedly decreased protein kinase A-dependent phospholamban and ryanodine receptor 2 phosphorylation (

41 Phosphorylation of phospholamban and ryanodine receptor was significantly i

42 e present study, we evaluated the effects of phospholamban and sarcolipin on calcium translocation an

43 However, how phospholamban and sarcolipin regulate SERCA is not fully

44 ice demonstrated no changes in expression of phospholamban and sarcoplasmic reticulum Ca(2+) ATPase,

45 ced CaMKIIdelta-dependent phosphorylation of phospholamban and the ryanodine receptor 2.

46 ted validated PKA and CaMKII target sites on phospholamban and the ryanodine receptor using genetical

47 s that regulate Ca(2+) handling in myocytes, phospholamban and the voltage-dependent L-type Ca(2+) ch

48 the SR appear to be due to STIM1 binding to phospholamban and thereby indirectly activating SERCA2a

49 acid further enhances the phosphorylation of phospholamban and TnI as well as contraction responses i

50 key role in limiting PKA phosphorylation of phospholamban and TnI for myocyte contraction responses

51 ation, yields maximal PKA phosphorylation of phospholamban and TnI, and myocyte contraction responses

52 ufficient for maximal PKA phosphorylation of phospholamban and TnI.

53 o a small increase in PKA phosphorylation of phospholamban and troponin I (TnI), and contraction resp

54 monstrated by decrease in phosphorylation of phospholamban and troponin I after beta-adrenergic stimu

55 ion and diffusion for PKA phosphorylation of phospholamban and troponin I, and for myocyte contractio

56 eptor complex but not for phosphorylation of phospholamban and troponin I.

57 reticulum Ca(2+) ATPase, increased levels of phospholamban and troponin T phosphorylation, and reduce

58 of extracellular signal-regulated kinase and phospholamban), and contraction.

59 activities at the SR, PKA phosphorylation of phospholamban, and contractile responses in PGE2-pretrea

60 other Ca2+ handling proteins, in particular phospholamban, and its phosphorylation status.

61 Increased phosphorylation of CaMKII, phospholamban, and ryanodine receptor 2 was detected in

62 oplasmic endoplasmic reticulum Ca(2+)ATPase, phospholamban, and ryanodine receptor proteins, as well

63 osin heavy chain, atrial natriuretic factor, phospholamban, and sarcoplasmic reticulum Ca2+-ATPase.

64 )-handling proteins (L-type Ca(2+) channels, phospholamban, and sarcoplasmic/endoplasmic reticulum ca

65 r2808 in ryanodine receptor type-2, Ser16 in phospholamban, and Ser23/24 in troponin-I were hyperphos

66 nalysis showed reduced levels of calmodulin, phospholamban, and SERCA2.

67 c markers alpha-actinin, myosin heavy chain, phospholamban, and tropomyosin was not observed at 2 wee

68 activities, promotes PKA phosphorylation of phospholamban, and ultimately enhances myocyte contracti

69 ulum calcium pump (SERCA) and its regulator, phospholamban, are essential components of cardiac contr

70 insight into how four hereditary mutants of phospholamban, Arg(9) to Cys, Arg(9) to Leu, Arg(9) to H

71 ition, the ISO-stimulated phosphorylation of phospholamban at Ser(16) was reduced by 27% in TG hearts

72 hosphorylation of other PKA targets, such as phospholamban at Ser16, phospholemman at Ser68 and cardi

73 rotein kinase A-dependent phosphorylation of phospholamban at Ser16.

74 ta(C) expression, whereas phosphorylation of phospholamban at Thr17, an endogenous indicator of CaMKI

75 se activity (p < 0.0004), phosphorylation of phospholamban (at Ser16 site; p = 0.04) and cardiac trop

76 culum Ca(2+)ATPase showed no recovery, while phospholamban, beta-adrenergic receptor, and the inotrop

77 chieved through increased phosphorylation of phospholamban by protein kinase A and relief of sarco/en

78 e calcium channel, sodium-calcium exchanger, phospholamban, calcineurin, and calcium/calmodulin-depen

79 Our results also indicated that phospholamban can establish an inhibitory interaction wi

80 doplasmic reticulum Ca2+ ATPase 2a (SERCA2a)/phospholamban complex contribute to heart failure.

81 Notably, S-nitrosylation of phospholamban consequent upon betaAR stimulation is nece

82 We conclude that STIM1 binding to phospholamban contributes to the regulation of SERCA2a a

83 Phospholamban deficiency rescued SR Ca(2+) content and S

84 uble-null mice also was partially rescued by phospholamban deletion.

85 ill-based experiments, we have characterized phospholamban dynamics in the micros-ms timescale.

86 ted that adenylyl cyclase VI reduces cardiac phospholamban expression.

87 ent with a role for PLM analogous to that of phospholamban for SR Ca-ATPase (SERCA): inhibition of Na

88 We demonstrate that the role of Arg(9) in phospholamban function is multifaceted: it is important

89 mine the phenotypic spectrum associated with phospholamban gene (PLN) mutations.

90 sarcoplasmic reticulum Ca2+ load related to phospholamban hyperphosphorylation and ryanodine recepto

91 ates with both SR calcium ATPase type 2a and phospholamban in a complex that also contains A-kinase a

92 mall transmembrane peptides, most notably by phospholamban in cardiac muscle and sarcolipin in skelet

93 al and cardiac SR are due to the presence of phospholamban in cardiac SR, and not due to isoform-depe

94 rol, P <0.05) and reduced phosphorylation of phospholamban in HF (Ser16, 30 +/- 10% and Thr17, 41 +/-

95 eduction in the extent of phosphorylation of phospholamban in the left ventricular myocardium of HF p

96 e of SR markers (calsequestrin, SERCA2a, and phospholamban) in pRHM, suggesting that the mitochondria

97 calcium ATPase SERCA, namely sarcolipin and phospholamban, in explicit lipid bilayers.

98 Phospholamban is a 52-amino acid membrane protein that r

99 These results suggest that phospholamban is an important component of the mechanism

100 The internal dynamics of phospholamban is characterized by large amplitude collec

101 tional sampling of monomeric, membrane-bound phospholamban is described from computer simulations.

102 SERCA2a is downregulated and phospholamban is hypophosphorylated in failing hearts, r

103 in saponin-permeabilized wild type (WT) and phospholamban knockout (PLB-KO) mouse ventricular myocyt

104 ent protein kinase (CaMKII) in permeabilized phospholamban knockout (PLN-KO) mouse myocytes phosphory

105 activity was also constitutively elevated in phospholamban-knockout antrum smooth muscle cells relati

106 The resting membrane potential of phospholamban-knockout antrum smooth muscle cells was hy

107 sence of SNP, STOC activity in wild-type and phospholamban-knockout antrum smooth muscle cells was in

108 in, inhibited STOC activity in wild-type and phospholamban-knockout antrum smooth muscle cells.

109 wave activity was significantly increased in phospholamban-knockout antrum smooth muscles compared to

110 smooth muscle cells to a greater extent than phospholamban-knockout antrum smooth muscles.

111 cells, but had no effect on STOC activity in phospholamban-knockout cells.

112 cells, but had no effect on STOC activity of phospholamban-knockout cells.

113 evated intracellular Ca(2+) wave activity of phospholamban-knockout cells.

114 ntrum smooth muscle cells from wild-type and phospholamban-knockout mice.

115 mproved cardiac BH(4) stores, phosphorylated phospholamban levels, and diastolic dysfunction.

116 ted) had 3-fold higher SERCA2a and 40% lower phospholamban levels.

117 Phospholamban modulates contractility by inhibiting SERC

118 Mechanistically, HAX-1 promoted formation of phospholamban monomers, the active/inhibitory units of t

119 with this, mice expressing a superinhibitory phospholamban mutant had low SR Ca(2+) content and slow

120 states of SERCA, we found that the effect of phospholamban on SERCA depends on substrate preincubatio

121 ements, proteoliposomes containing SERCA and phospholamban or sarcolipin were adsorbed to a solid-sup

122 handling proteins was not (calsequestrin and phospholamban) or was minimally (SERCA) affected.

123 n phosphorylation of troponin I, troponin T, phospholamban, or myosin light chain-1 or -2.

124 hosphorylation of cardiac troponin I (cTnI), phospholamban, or ryanodine receptor (RyR2).

125 rdiac ankyrin repeat protein (p < 0.01), and phospholamban (p < 0.05).

126 cular complexes of SR calcium ATPase type 2a-phospholamban-PDE3A.

127 edicted by a computer molecular model of the phospholamban pentamer constructed from NMR solution str

128 n kinase A recognition in the context of the phospholamban pentamer.

129 h increases in cAMP generation (P = 0.0002), phospholamban phosphorylation (P < 0.04), sarcoplasmic r

130 cAMP levels, PDE activity, and phospholamban phosphorylation (pPLB) were determined in

131 ibitor-1 results in selective enhancement of phospholamban phosphorylation and augmented cardiac cont

132 ctile function, associated with preferential phospholamban phosphorylation and enhanced sarcoplasmic

133 I-1 knockout mice lack phospholamban phosphorylation and exhibit vascular smoot

134 s likely through reduced apoptosis, enhanced phospholamban phosphorylation and improved Akt/mTOR/p70S

135 kinase A recognition motif, which abrogates phospholamban phosphorylation and results in constitutiv

136 eased ryanodine receptor phosphorylation and phospholamban phosphorylation at both the Ser16 and Thr1

137 sed expression of protein kinase A-dependent phospholamban phosphorylation at Ser16 and CaMKII (Ca(2+

138 ](i) decline (by 28%; n=12, all P<0.05), and phospholamban phosphorylation at Ser16, but Ca current w

139 RCA2a) protein expression and an increase in phospholamban phosphorylation at serine 16, similar to h

140 dulin-dependent protein kinase II)-dependent phospholamban phosphorylation at Thr17.

141 Phospholamban phosphorylation by protein kinase A (PKA)

142 i/o inhibitor pertussis toxin normalized the phospholamban phosphorylation by protein kinase A, rever

143 basal PKA activity, indexed by gradations in phospholamban phosphorylation effected by a specific PKA

144 Elevated Nox2 activity increased phospholamban phosphorylation in both hearts and cardiom

145 ype 2a activity, SR Ca(2+) uptake rates, and phospholamban phosphorylation in SR fractions.

146 Cyclopiazonic acid and graded changes in phospholamban phosphorylation produced by beta-adrenergi

147 In addition, phospholamban phosphorylation was reduced (P=0.015), sar

148 Total phospholamban phosphorylation was unaltered, although it

149 ed cAMP-mediated, protein kinase A-dependent phospholamban phosphorylation, and increased SANC firing

150 blot analysis showed a fourfold increase in phospholamban phosphorylation, and PKA activity increase

151 s highly expressed, leading to a decrease in phospholamban phosphorylation, sarco/endoplasmic reticul

152 In parallel with the phospholamban phosphorylation, the decay kinetics of glo

153 We speculate that phospholamban phosphorylation, through activation of Akt

154 leucine eliminate both SERCA inhibition and phospholamban phosphorylation, whereas an aromatic subst

155 tudies is how adenylyl cyclase VI influences phospholamban phosphorylation.

156 ects, and loss of protein kinase A-dependent phospholamban phosphorylation.

157 lude ancillary effects of CaMKII mediated by phospholamban phosphorylation.

158 es suggest that PLN-Ab mimics the effects of phospholamban phosphorylation.

159 function through redox-regulated changes in phospholamban phosphorylation.

160 Phospholamban (PLB) and phospholemman (PLM, also called

161 ATPase (SERCA) pump activity is modulated by phospholamban (PLB) and sarcolipin (SLN) in cardiac and

162 protein binding interactions between native phospholamban (PLB) and SERCA2a in sarcoplasmic reticulu

163 actions between the transmembrane domains of phospholamban (PLB) and the cardiac Ca2+ pump (SERCA2a)

164 or presence of the SERCA regulatory partner, phospholamban (PLB) and were unaltered by PLB phosphoryl

165 egulatory role of the C-terminal residues of phospholamban (PLB) in the membranes of living cells, we

166 Here we test whether phospholamban (PLB) inhibition using a dominant-negative

167 Phospholamban (PLB) inhibits the activity of SERCA2a, th

168 Phospholamban (PLB) is a 52 amino acid membrane-endogeno

169 Phospholamban (PLB) is a 52-amino acid integral membrane

170 Phospholamban (PLB) is a pentameric transmembrane protei

171 Phospholamban (PLB) is a small transmembrane protein tha

172 Given that phospholamban (PLB) is robustly present in adult but poo

173 e measured in-gel fluorescence anisotropy of phospholamban (PLB) labeled with the biarsenical fluorop

174 Three cross-linkable phospholamban (PLB) mutants of increasing inhibitory str

175 Phospholamban (PLB) oligomerization, quaternary structur

176 Phospholamban (PLB) or the sarcoplasmic reticulum Ca2+-A

177 oblot method to measure the mole fraction of phospholamban (PLB) phosphorylated at Ser16 (X(p)) in bi

178 We have studied the differential effects of phospholamban (PLB) phosphorylation states on the activi

179 Phospholamban (PLB) physically interacts with Ca(2+)-ATP

180 Phospholamban (PLB) plays a key role as a regulator of s

181 that the cAMP-responsive-like element in the phospholamban (PLB) promoter was critical for down-regul

182 Our model of phospholamban (PLB) regulation of the cardiac Ca(2+)-ATP

183 e kinetic assays to test the hypothesis that phospholamban (PLB) stabilizes the Ca-ATPase in the E2 i

184 loss-of-function mutants, L31A and L31C, of phospholamban (PLB) to bind to and inhibit the Ca(2+) pu

185 A naturally occurring R9C mutation of phospholamban (PLB) triggers cardiomyopathy and prematur

186 e, protein kinase A (PKA) phosphorylation of phospholamban (PLB) was decreased, whereas PKA phosphory

187 sites on the ryanodine receptor (RyR) and on phospholamban (PLB) were increased in CaMKIIdelta(C) TG.

188 e polypeptide chains and their modulation by phospholamban (PLB) were measured in native cardiac sarc

189 ct of phosphorylation on the interactions of phospholamban (PLB) with itself and its regulatory targe

190 performed molecular dynamics simulations of phospholamban (PLB), a 52-residue integral membrane prot

191 on and mutation on the cytoplasmic domain of phospholamban (PLB), a 52-residue protein that regulates

192 In cardiac muscle, SERCA is regulated by phospholamban (PLB), a small inhibitory phosphoprotein t

193 SERCA activity in muscle can be regulated by phospholamban (PLB), an affinity modulator, and sarcolip

194 oplasmic reticulum Ca(2+) ATPase 2 (SERCA2), phospholamban (PLB), and AKAP18 in a multiprotein signal

195 ) uptake adenosine triphosphatase (SERCA2a), phospholamban (PLB), and increased PLB phosphorylation (

196 al dynamics of an integral membrane protein, phospholamban (PLB), and thereby its functional inhibiti

197 evel of calsequestrin, Na+/Ca2+ exchanger or phospholamban (PLB), but with both RyR2 and PLB hyperpho

198 but is associated with dephosphorylation of phospholamban (PLB), decreased sarcoplasmic reticulum Ca

199 al dynamics of an integral membrane protein, phospholamban (PLB), in a lipid bilayer.

200 doplasmic reticulum Ca(2+)-ATPase (SERCA) by phospholamban (PLB), we expressed Cerulean-SERCA and yel

201 ATPase] and SERCA2a calcium pump isoforms by phospholamban (PLB), we quantified PLB-SERCA interaction

202 ce (EPR) to probe the functional dynamics of phospholamban (PLB), which regulates the Ca-ATPase (SERC

203 s cAMP- and PKA-dependent phosphorylation of phospholamban (PLB), which relieves the inhibitory effec

204 eticulum Ca-ATPase (SERCA) and its regulator phospholamban (PLB).

205 coplasmic reticulum Ca-ATPase (SERCA2a), and phospholamban (PLB).

206 erminal membrane-spanning helical domains of phospholamban (PLB).

207 culum Ca(2+)-ATPase (SERCA)) in complex with phospholamban (PLB).

208 Hence like phospholamban, PLM exists as a pump-inhibiting monomer a

209 We hypothesized that phospholamban (PLN) ablation would restore SR Ca(2+) loa

210 Phospholamban (PLN) and sarcolipin (SLN) are two single-

211 es structural and functional similarity with phospholamban (PLN) and sarcolipin (SLN), which inhibit

212 ated by the small integral membrane proteins phospholamban (PLN) and sarcolipin (SLN).

213 on with the short integral membrane proteins phospholamban (PLN) and sarcolipin (SLN).

214 he integral membrane protein complex between phospholamban (PLN) and sarcoplasmic reticulum Ca(2+)-AT

215 um ATPase (SERCA) and its regulatory partner phospholamban (PLN) are essential for myocardial contrac

216 ith specific increases in phosphorylation of phospholamban (PLN) at both Ser16 and Thr17, relieving i

217 ated with decreased (50%) phosphorylation of phospholamban (PLN) at serine 16, whereas phosphorylatio

218 )plasmic reticulum Ca(2+)-ATPase (SERCA) and phospholamban (PLN) complex regulates heart relaxation t

219 oplasmic reticulum Ca(2+)-ATPase (SERCA) and phospholamban (PLN) controls Ca(2+) transport in cardiom

220 A mutation in the coding region of the phospholamban (PLN) gene (R14del) is identified in famil

221 Mutations in the phospholamban (PLN) gene are associated with dilated car

222 14 (PLN-R14Del) in the coding region of the phospholamban (PLN) gene in a large family with heredita

223 Ablation or inhibition of phospholamban (PLN) has favorable effects in several gen

224 ative roles of cardiac troponin I (cTnI) and phospholamban (PLN) in beta-adrenergic-mediated hastenin

225 Phospholamban (PLN) is a type II membrane protein that i

226 Phospholamban (PLN) is an effective inhibitor of the sar

227 Phospholamban (PLN) is an essential regulator of cardiac

228 A 52-residue membrane protein, phospholamban (PLN) is an inhibitor of an adenosine-5'-t

229 Phospholamban (PLN) is an inhibitor of cardiac sarco(end

230 Phospholamban (PLN) is an inhibitor of the Ca2+ affinity

231 rogression of LV disease was associated with phospholamban (PLN) mutation (OR, 8.8; 95% CI, 2.1-37.2;

232 decreased cardiac contractility with reduced phospholamban (PLN) phosphorylation at serine-16, the ma

233 Phospholamban (PLN) plays a central role in Ca(2+) homeo

234 Phospholamban (PLN) regulates calcium translocation with

235 Phospholamban (PLN) regulates cardiac contractility via

236 The regulatory interaction of phospholamban (PLN) with Ca(2+)-ATPase controls the upta

237 In cardiomyocytes, PKA targets phospholamban (PLN), a membrane protein that inhibits th

238 expression, phosphorylation, and function of phospholamban (PLN), a sarcoendoplasmic reticulum regula

239 Phospholamban (PLN), a single-pass membrane protein, reg

240 0% identity with the transmembrane domain of phospholamban (PLN), and recent solution NMR studies car

241 Human phospholamban (PLN), expressed in the sarcoplasmic retic

242 nd interacts with the small membrane protein phospholamban (PLN), inhibiting the cardiac sarco/endopl

243 nd Phd3 dramatically decreased expression of phospholamban (PLN), resulted in sustained activation of

244 hatase 1 modulate the inhibitory activity of phospholamban (PLN), the endogenous regulator of the sar

245 tion with SERCA2a or its regulatory protein, phospholamban (PLN), we measured its effects on SERCA2a

246 in complex formed by Ca2+-ATPase (SERCA) and phospholamban (PLN), which in humans is responsible for

247 We generated phospholamban (PLN)-deficient S2814D(+/+) knock-in mice

248 We generated phospholamban (PLN)-deficient/S2814D(+/+) knock-in mice

249 ), whose activity is reversibly regulated by phospholamban (PLN).

250 ing the L-type Ca(2+) channel (Ca(V)1.2) and phospholamban (PLN).

251 phorylation of cardiac troponin I (cTnI) and phospholamban (PLN).

252 ecreased CaMKII-dependent phosphorylation of phospholamban (PLN).

253 in a manner similar to that of its homologue phospholamban (PLN).

254 Phospholamban protein expression was reduced 50%, but th

255 Although total phospholamban protein expression was unchanged, there wa

256 asmic endoplasmic reticular calcium ATPase 2/phospholamban protein ratio (45% reduced; P=0.03).

257 r sarcoplasmic reticulum Ca2+ ATPase pump to phospholamban protein ratio in SAN than in right atrium.

258 SERCA2a and phospholamban protein were unchanged in MR versus contro

259 Phospholamban R14del mutation carriers are at high risk

260 ee mortality ratio method in a cohort of 403 phospholamban R14del mutation carriers, we found a stand

261 gnant ventricular arrhythmias in a cohort of phospholamban R14del mutation carriers.

262 The pathogenic phospholamban R14del mutation causes dilated and arrhyth

263 Much like phospholamban regulation of SERCA, phospholemman exists

264 speed of atrial contraction independently of phospholamban regulation.

265 e redundantly to phosphorylation not only of phospholamban, ryanodine receptor 2, and histone deacety

266 DHF reduced phospholamban, ryanodine receptor, and sarcoplasmic reti

267 e receptor 2 phosphorylation (-42+/-9% for P-phospholamban-S16 and -22+/-7% for P-ryanodine receptor

268 activity by displacing the SERCA inhibitors, phospholamban, sarcolipin, and myoregulin.

269 12), which regulate Na(+) ,K(+) -ATPase, and phospholamban, sarcolipin, myoregulin and DWORF, which r

270 r, HAX-1 sequestered Hsp90 from IRE-1 to the phospholamban-sarcoplasmic/endoplasmic reticulum calcium

271 c hearts showed increased phosphorylation of phospholamban Ser-16 and Thr-17 compared with the alpha-

272 in SERCA2a expression and phosphorylation of phospholamban Ser-16.

273 he kinase selectively phosphorylates cardiac phospholamban Ser16-a site important for diastolic relax

274 estern blot analyses revealed decreases in p-phospholamban, SERCA2a, p-CX43, p-GSK-3alpha/beta, nucle

275 reticulum Ca(2+) leak/load relationship) and phospholamban Serine16 phosphorylation (Western blot).

276 Phosphorylated phospholamban stabilizes a unique conformation of SERCA

277 way analogous to the regulation of SERCA by phospholamban-that is un-phosphorylated PLM exerts a ton

278 Earlier studies have shown that SLN and phospholamban, the other well studied small SERCA-regula

279 In the case of phospholamban, the restrained ensemble sampled the confo

280 Agonist-evoked phosphorylation by CaMKII at phospholamban (Thr-17), but not of ryanodine2 (Ser-2814)

281 the ryanodine receptor (RyR2) (Ser2815) and phospholamban (Thr17) in a PKC-dependent manner.

282 acetylase 5 phosphorylation (Ser498) but not phospholamban (Thr17), whereas the converse holds for ca

283 memory in the interaction between SERCA and phospholamban, thus providing insights into the physiolo

284 ype Ca(2+) channels, ryanodine receptors and phospholamban to basal levels.

285 estration, since the ratio of phosphorylated phospholamban to total phospholamban was sharply reduced

286 s--glycophorin A, the M2 proton channel, and phospholamban--using only peptide sequence and the nativ

287 eased PKA phosphorylation of cTnI, RyR2, and phospholamban versus controls.

288 The CaMKII target pT17-phospholamban was 5.5-fold increased only in sarcomere-m

289 sphorylation of the SERCA regulatory protein phospholamban was increased in cells cultured under 5% O

290 activation) of the SERCA2a-inhibitor protein phospholamban was increased in pAF.

291 earts of female mice, whereas phosphorylated phospholamban was increased.

292 Although phosphorylation of phospholamban was not altered, miR-1 overexpression incr

293 tio of phosphorylated phospholamban to total phospholamban was sharply reduced in all three mutant he

294 PI3Kgamma(-/-) cardiomyocytes, Ca(v)1.2 and phospholamban were hyperphosphorylated, leading to incre

295 asmic endoplasmic reticulum Ca(2+)ATPase and phospholamban were normal in left ventricular hypertroph

296 essary for the inhibitory pentamerization of phospholamban, which activates sarcoplasmic reticulum Ca

297 HAX-1 were abolished upon phosphorylation of phospholamban, which plays a fundamental role in control

298 Much like phospholamban, which regulates the related ATPase SERCA,

299 ational design of a water-soluble variant of phospholamban, WSPLB, which reproduced many of the struc

300 ide chain and backbone dynamics of wild-type phospholamban (WT-PLB) and its phosphorylated form (P-PL